Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | The value of CAR-T cell therapy for the treatment of R/R multiple myeloma

Thomas Martin • 30 Sep 2022
SOHO 2022
Multiple Myeloma CAR-T Ciltacabtagene autoleucel Idecabtagene vicleucel
KarMMa

Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, shares some insights into the value of CAR-T cell therapy for the treatment of patients with relapsed/refractory (R/R) multiple myeloma, commenting on the impressive overall response rates (ORR) observed in heavily pre-treated patients. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Thomas Martin

4:03
IKEMA long-term sub-group analysis: Isa-Kd for 1q21+ multiple myeloma
Thomas Martin • 11 Sep 2023
2:57
Considerations for mitigating CAR-T resistance in multiple myeloma
Thomas Martin • 11 Sep 2023
4:14
Challenges with the real-world use of CAR-T therapy in multiple myeloma
Thomas Martin • 11 Sep 2023
9:52
Myeloma highlights from SOHO 2023: updates with the use of novel targeted immunotherapies
Thomas Martin • 11 Sep 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals